METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST Russian patent published in 2022 - IPC A61K39/395 C07K16/28 A61P37/08 

FIELD: pharmaceutical industry.

SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a method for reducing serum allergen-specific IgE in a patient and to the use of an interleukin-4 receptor antagonist (IL-4R) to reduce serum allergen-specific IgE in a patient with an elevated level of serum allergen-specific IgE. A method for reducing serum allergen-specific IgE in a patient, including: administration to a patient with atopic dermatitis, asthma and/or allergic rhinitis, a therapeutically effective amount of an interleukin-4 receptor antagonist (IL-4R), and before or during treatment, the patient has a serum allergen-specific IgE level of 0.35 kU/ml at determination by immunoassay, and the allergen comes from a source selected from a group consisting of gray alder, black rot, Bermuda grass, silver birch, cat dandruff, cladosporium, cockroach, Dermatophagoides farinae, D. pteronyssinus, dog dandruff, elm, Johnson's grass, white oak, ragweed, timothy, white ash, white candida, Malasezzia furfur, Pityrosporum orbiculare, mold, staphylococcal enterotoxin A and staphylococcal enterotoxin B; moreover, the IL-4R antagonist is an antibody or its antigen-binding fragment that specifically bind IL-4Rα, and contains three complementarity-determining regions of the heavy chain (HCDR1, HCDR2 and HCDR3) and three complementarity-determining regions of the light chain (LCDR1, LCDR2 and LCDR3), where HCDR1 contains the amino acid sequence SEQ ID NO: 3; HCDR2 contains the amino acid sequence SEQ ID NO: 4; HCDR3 contains the amino acid sequence SEQ ID NO: 5; LCDR1 contains the amino acid sequence SEQ ID NO: 6; LCDR2 contains the amino acid sequence SEQ ID NO: 7 and LCDR3 contains the amino acid sequence SEQ ID NO:8, wherein the IL-4R antagonist is administered for at least 16 weeks, wherein the IL-4R antagonist is administered in an initial dose followed by one or more secondary doses, where each secondary dose is administered after 1-4 weeks after the immediately preceding dose, and moreover: i) the initial dose contains 600 mg and each secondary dose contains 300 mg of an IL-4R antagonist, or ii) the initial dose contains 400 mg and each secondary dose contains 200 mg of an IL-4R antagonist. The use of an interleukin-4 receptor antagonist (IL-4R) to reduce serum allergen-specific IgE in a patient with elevated serum allergen-specific IgE. The use of an interleukin-4 receptor antagonist (IL-4R) to obtain a drug to reduce serum allergen-specific IgE in a patient with an elevated level of serum allergen-specific IgE.

EFFECT: above-described method and application make it possible to more effectively reduce serum allergen-specific IgE in a patient with an elevated level of serum allergen-specific IgE.

23 cl, 11 dwg, 3 tbl, 4 ex